deltatrials
Unknown OBSERVATIONAL NCT04769245

The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection

The Effectiveness of ACB-IP 1.0 Universal Pathogen Free Concentrated Cocktail Convalescent Plasma in COVID-19 Infection

Sponsor: Acibadem University

Conditions Covid19
Updated 5 times since 2021 Last updated: Feb 23, 2021 Started: Feb 18, 2021 Primary completion: Apr 1, 2021 Completion: Jun 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Covid19, this trial is ongoing. The trial is conducted by Acibadem University and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Mar 2021 – ~Mar 2023 · 24 months · monthly snapshotRecruiting~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 10 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  4. Mar 2023 — Jul 2024 [monthly]

    Unknown Status

    Status: Recruiting → Unknown Status

  5. Mar 2021 — Mar 2023 [monthly]

    Recruiting

    First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Acibadem University
  • Acıbadem Labcell
Data source: Acibadem University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations